4D Molecular Therapeutics Profit Margin

4D Molecular Therapeutics (FDMT) currently reports a profit margin of -188.86% as of March 2026. That compares with -17643900.0% in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore 4D Molecular Therapeutics's profit margin history and peer comparisons.

4D Molecular Therapeutics's profit margin increased from -17643900.0% to -188.86% — a 100.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

4D Molecular Therapeutics's profit margin of -188.86% is lower than the Healthcare sector average of 14.34%. That is roughly 1416.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but 4D Molecular Therapeutics's current -188.86% should be judged against Healthcare norms (sector average: 14.34%) and against FDMT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -188.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for 4D Molecular Therapeutics, and consider following FDMT for alerts when major investors trade the stock.